Blog
Dose Selection in Proof-of-Concept Trials: When to use a single “no regret” dose versus multi-dose evaluation
Our latest white paper, by Senior Clinical Pharmacologist Dr Simon Hutchings, looks at one of the most important decisions in early development: whether to back a single “no-regret” dose or generate evidence across multiple doses first.
The paper explores how dose strategy shapes interpretability, regulatory confidence, and programme risk, with examples from Alzheimer’s disease, oncology, and adaptive trial design.
>200 companies
We have advised, worked with and supported dozens of funds and biotechs.
>500 million plus
Our input is benefitting patient populations worldwide.
>25 billion USD
Our repeat and long-term clients have realised significant value gains since we became involved in their programmes.